Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.
Publication
, Conference
Philips, G; Halabi, S; Sanford, B; Bajorin, D; Small, E
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
391S / 391S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Philips, G., Halabi, S., Sanford, B., Bajorin, D., & Small, E. (2004). Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 391S-391S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
Philips, G., S. Halabi, B. Sanford, D. Bajorin, and E. Small. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.” In JOURNAL OF CLINICAL ONCOLOGY, 22:391S-391S. AMER SOC CLINICAL ONCOLOGY, 2004.
Philips G, Halabi S, Sanford B, Bajorin D, Small E. Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 391S-391S.
Philips, G., et al. “Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, AMER SOC CLINICAL ONCOLOGY, 2004, pp. 391S-391S.
Philips G, Halabi S, Sanford B, Bajorin D, Small E. Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 391S-391S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
391S / 391S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences